Job Trends
Labor Market Reports
Among those who connected salary increases to swapping out employers, 75% saw pay rise by at least 6%, and the most often cited increase was 10%, according to the just-released BioSpace salary report.
BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a clinical job? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Last month, for the first time in nearly four years, average job postings live on BioSpace did not decline year over year. In another encouraging sign, the number of biopharmas letting employees go fell.
Career Advice
Recruiters can play a significant role in biopharma professionals getting hired, especially in an employer-driven job market. However, when working with them, candidates need to avoid making six key mistakes, from waiting too long to ask for help to prematurely contacting hiring companies.
THE LATEST
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
AstraZeneca’s COVID-19 vaccine road to approval has been anything but smooth.
The U.S. FDA’s Oncologic Drugs Advisory Committee did not agree in a recent meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.
AstraZeneca reported its first-quarter financial reports. As is often the case, they updated their pipeline, and indicated they had dropped a few drugs, including a promising multiple myeloma drug.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
The battle against COVID-19 rages on, and other therapeutics are making their way through the clinic, including monoclonal antibody treatments and antivirals. BioSpace takes a look at some of the ongoing efforts to stem the rate of infection from the virus.
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.
What makes this particularly surprising is that in July 2020, mirikizumab hit all primary endpoints against placebo and secondary endpoints against Novartis’ Cosentyx in a Phase III OASIS-2 study of plaque psoriasis.
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look.
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.